Trials / Terminated
TerminatedNCT00996255
Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors
A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1-hour IV Infusion on Days 1, 8 and 15 in a 4-Week Cycle in Patients With Advanced/Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHA-793887 | Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles. |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2009-10-16
- Last updated
- 2009-10-16
Locations
2 sites across 2 countries: France, United Kingdom
Source: ClinicalTrials.gov record NCT00996255. Inclusion in this directory is not an endorsement.